These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38529661)

  • 21. Quinolone-based HDAC inhibitors.
    Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
    Valente S; Trisciuoglio D; De Luca T; Nebbioso A; Labella D; Lenoci A; Bigogno C; Dondio G; Miceli M; Brosch G; Del Bufalo D; Altucci L; Mai A
    J Med Chem; 2014 Jul; 57(14):6259-65. PubMed ID: 24972008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
    Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
    Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
    Lu Y; Feng Y; Li Z; Li J; Zhang H; Hu X; Jiang W; Shi T; Wang Z
    Eur J Med Chem; 2022 Jan; 227():113908. PubMed ID: 34656900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.
    Di Bello E; Sian V; Bontempi G; Zwergel C; Fioravanti R; Noce B; Castiello C; Tomassi S; Corinti D; Passeri D; Pellicciari R; Mercurio C; Varasi M; Altucci L; Tripodi M; Strippoli R; Nebbioso A; Valente S; Mai A
    Eur J Med Chem; 2023 Feb; 247():115022. PubMed ID: 36549114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
    Barrett RRG; Nash C; Diennet M; Cotnoir-White D; Doyle C; Mader S; Thomson AA; Gleason JL
    Bioorg Med Chem Lett; 2022 Jan; 55():128441. PubMed ID: 34767912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
    Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
    Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC /microRNA regulation.
    Mekala JR; Ramalingam PS; Mathavan S; Yamajala RBRD; Moparthi NR; Kurappalli RK; Manyam RR
    Chem Biol Interact; 2022 Apr; 357():109876. PubMed ID: 35283086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
    El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
    Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
    Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA
    ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
    Reddy RG; Bhat UA; Chakravarty S; Kumar A
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
    Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
    Cheng J; Qin J; Guo S; Qiu H; Zhong Y
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.